Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia
Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.
Related Articles
Glofitamab/GemOx Enhances OS and PFS vs Rituximab in R/R DLBCL
Glofitamab plus gemcitabine/oxaliplatin demonstrated improved PFS and OS compared with rituximab in patients with relapsed/refractory DLBCL.
Cilta-Cel Boosts Survival Vs SOC Across Key Subgroups of R/R Multiple Myeloma
CARTITUDE-4 subgroup data further support cilta-cel’s positive benefit-risk profile in relapsed/refractory multiple myeloma.
Relacorilant Combo Improves PFS, Trends Toward Superior OS in Platinum-Resistant Ovarian Cancer
Relacorilant plus nab-paclitaxel showed meaningful PFS and OS gains, offering a potential new option for patients with platinum-resistant ovarian cancer.
FDA Grants Priority Review to Ziftomenib in NPM1-Mutant R/R AML
The FDA has granted priority review to ziftomenib for relapsed/refractory acute myeloid leukemia harboring an NPM1 mutation.
Sevabertinib Induces Durable Response in Advanced HER2-Mutant NSCLC
Treatment with the oral TKI showed promising responses among 2 subgroups of patients with advanced, HER2-mutant non–small cell lung cancer.
Sintilimab/Chidamide Plus P-GemOx Shows Antitumor Activity in Treatment-Naive, Early-Stage Natural Killer/T-Cell Lymphoma
Sintilimab/chidamide followed by P-GemOx demonstrated preliminary efficacy in treatment-naive, early-stage extranodal natural killer/T-cell lymphoma.
Generic Eltrombopag Is Now Available for Severe Aplastic Anemia and Immune Thrombocytopenia
Generic formulations of eltrombopag are now available for severe aplastic anemia and immune thrombocytopenia.
Optimizing Ovarian Cancer Care: PARP Resistance, Management of Oligoprogression, and Adverse Event Mitigation
Panelists discuss strategies to address PARP inhibitor (PARPi) resistance in ovarian cancer, including emerging combinations like gotistobart + pembrolizumab from the PRESERVE-004 trial, insights from the SOPRANO…
National Fellows Forum: Lung Cancer
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Lutetium Lu 177 Vipivotide Tetraxetan Generates rPFS Improvement in PSMA+ mHSPC
Lutetium Lu 177 vipivotide tetraxetan plus hormone therapy yielded rPFS and OS benefits vs hormone therapy alone in patients with PSMA-positive mHSPC.